A randomized, multicenter, open-label, phase 2b study of VELCADE [bortezomib] alone and VELCADE plus irinotecan in patients with relapsed or refractory colorectal carcinoma

Trial Profile

A randomized, multicenter, open-label, phase 2b study of VELCADE [bortezomib] alone and VELCADE plus irinotecan in patients with relapsed or refractory colorectal carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2008

At a glance

  • Drugs Bortezomib; Irinotecan
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jul 2008 Results have been published.
    • 13 Feb 2008 The expected completion date for this trial is now 1 Mar 2004.
    • 08 Feb 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top